A controlled family study of cannabis users with and without psychosis

Schizophrenia Research

Volumn 152, Issue 1, 2014, Pages 283-288

  Proal, Ashley C ^a   Fleming, Jerry ^a,b   Galvez Buccollini, Juan A ^a,b   DeLisi, Lynn E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS;

ADOLESCENCE; ADOLESCENT; ADULT; ARTICLE; BIPOLAR DISORDER; CANNABIS USE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG ABUSE; FAMILY STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELATIVE; SCHIZOPHRENIA; STRUCTURED INTERVIEW;

FAMILY; FAMILY HEALTH; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA;

EID: 84891623824     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.11.014     Document Type: Article

References (20)

1. Andréasson S., Allebeck P., Rydberg U. Schizophrenia in users and nonusers of cannabis. A longitudinal study in Stockholm County. Acta Psychiatr. Scand. 1989, 79(5):505-510.
2. Boydell J., Dean K., Dutta R., Giouroukou E., Fearon P., Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr. Res. 2007, 93(1-3):203-210.
3. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene×environment interaction. Biol. Psychiatry 2005, 57(10):1117-1127.
4. Compton M.T., Kelley M.E., Ramsay C.E., Pringle M., Goulding S.M., Esterberg M.L., Stewart T., Walker E.F. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am. J. Psychiatry 2009, 166(11):1251-1257.
5. Deiana S. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?. Drug Test Anal. 2013, 5(1):46-51.
6. Fuchs C., Steinberg D.M., Poyurovsky M. On the estimation and comparison of lifetime morbid risks. J Data Sci. 2010, 8(4):645-664.
7. Galvez-Buccollini J.A., Proal A.C., Tomaselli V., Trachtenberg M., Coconcea C., Chun J., Manschreck T., Fleming J., Delisi L.E. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr. Res. 2012, 139(1-3):157-160.
8. Gershon E.S., DeLisi L.E., Hamovit J., Nurnberger J.I., Maxwell M.E., Schreiber J., Dauphinais D., Dingman C.W., Guroff J.J. A controlled family study of chronic psychoses. Schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 1988, 45(4):328-336.
9. Glatt S.J., Faraone S.V., Tsuang M.T. Association between a functional catechol-O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. Am. J. Psychiatry 2003, 160(3):469-476. (Review).
10. McGuire P.K., Jones P., Harvey I., Williams M., McGuffin P., Murray R.M. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr. Res. 1995, 15(3):277-281. (PMID: 7632625).
11. Merikangas K.R., Stolar M., Stevens D.E., Goulet J., Preisig M.A., Fenton B., Zhang H., O'Malley S.S., Rounsaville B.J. Familial transmission of substance use disorders. Arch. Gen. Psychiatry 1998, 55(11):973-979.
12. Merikangas K.R., Li J.J., Stipelman B., Yu K., Fucito L., Swendsen J., Zhang H. The familial aggregation of cannabis use disorders. Addiction 2009, 104(4):622-629.
13. NIH Family Interview for Genetics Study (FIGS): A Manual for FIGS. Clinical Neurogenetics Branch, Intramural Research Program 1992, National Institute of Mental Health, Bethesda, MA.
14. Nurnberger J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch. Gen. Psychiatry 1994, 51(11):849-859.
15. Smoller J.W. Disorders and borders: psychiatric genetics and nosology. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013, 162(7):559-578. 10.1002/ajmg.b.32174.
16. Suchanek R., Owczarek A., Paul-Samojedny M., Kowalczyk M., Kucia K., Kowalski J. BDNF val66met polymorphism is associated with age at onset and intensity of symptoms of paranoid schizophrenia in a Polish population. J. Neuropsychiatry Clin. Neurosci. 2013, 25(1):88-94.
17. Tovilla-Zárate C., Medellín B.C., Fresán A., López-Narváez L., Castro T.B., Juárez Rojop I., Ramírez-Bello J., Genis A., Nicolini H. No association between catechol-O-methyltransferase Val108/158Met polymorphism and schizophrenia or its clinical symptomatology in a Mexican population. Mol. Biol. Rep. 2012, 40(2):2053-2058.
18. Varma S.L., Sharma I. Psychiatric morbidity in the first-degree relatives of schizophrenic patients. Br. J. Psychiatry 1993, 162:672-678.
19. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325(7374):1199.
20. Zammit S., Spurlock G., Williams H., Norton N., Williams N., O'Donovan M.C., Owen M.J. Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco and cannabis use. Br. J. Psychiatry 2007, 191:402-407.